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INTRODUCTION
Colorectal cancer (CRC) is a major public health problem, be-
ing the third most commonly diagnosed cancer and the fourth 
cause of cancer death worldwide.1 In Korea, CRC was predict-
ed to be the third leading cause of cancer death in 2017.2 Al-
though the survival rate of CRC has improved gradually, ow-
ing to early screening programs, new surgical techniques, and 
the development of more-effective systemic therapies, most 
patients with metastatic or recurrent CRC face death, with a 
median survival time of 30 months.3 To develop future treat-
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Purpose: Dysregulation of the Wnt pathway is a crucial step in the tumorigenesis of colorectal cancer (CRC). This study aimed to 
determine whether DNA methylation of Wnt pathway genes helps predict treatment response and survival in patients with meta-
static or recurrent CRC. 
Materials and Methods: We retrospectively collected primary tumor tissues from 194 patients with metastatic or recurrent CRC. 
Pyrosequencing was used to examine the methylation of 10 CpG island loci in DNA extracted from formalin-fixed paraffin-em-
bedded specimens. To elucidate the predictive role of DNA methylation markers, Kaplan-Meier survival estimation and Cox re-
gression were performed for progression-free survival and overall survival (OS). 
Results: The methylation frequencies of the 10 genes analyzed (p16, p14, MINT1, MINT2, MINT31, hMLH1, DKK3, WNT5A, 
AXIN2, and TFAP2E) were 47.9%, 10.8%, 21.1%, 16.0%, 20.6%, 0.5%, 53.1%, 32.0%, 2.6%, and 2.1%, respectively. We divided pa-
tients into three groups based on the number of methylated genes (group 1, no methylation n=38; group 2, 1−2 methylations 
n=92; group 3, 3 or more methylations n=64). Among patients treated with palliative chemotherapy (n=167), median OSs of groups 
1, 2, and 3 were 39.1, 39.7, and 29.1 months, respectively (log rank p=0.013). After adjustment, number of methylations was iden-
tified as an independent poor prognostic factor (0−2 methylated vs. ≥3 methylated: hazard ratio, 1.72; 95% confidence interval, 
1.16−2.56, p=0.007).
Conclusion: This study suggests that methylation of Wnt pathway genes, in addition to known CpG island methylator phenotype 
markers, may help predict treatment outcome and survival in patients with CRC.  
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ment strategies and prolong the survival of CRC patients, it is 
crucial to identify the molecular characteristics of CRC, either 
genomic or epigenomic. 
CpG island methylator phenotype (CIMP) is a distinct sub-
type of various cancers, characterized by an increased frequen-
cy of aberrant promoter hypermethylation at specific loci. In 
cancers with CIMP, aberrant methylation of cytosine nucleo-
tides within these CpG islands can lead to silencing of tumor-
suppressor genes, which in turn promotes cancer develop-
ment. CIMP is reproducibly observed in approximately 15% 
of CRC cases, and the subgroup defined as CIMP is character-
ized with high rates of KRAS or BRAF mutation.4-6 A recent me-
ta-analysis showed that CRC patients with CIMP have a worse 
prognosis than those without CIMP.7 The CIMP subtype is more 
enriched in the right side colon when compared with the left 
side colon, thereby conferring a prognostic impact on CRC.7,8   
Aberrant activation of the Wnt signaling pathway is one of 
the first events in CRC carcinogenesis. Genomic and epigenom-
ic abnormalities in genes regulating the Wnt pathway, such as 
APC and AXIN2, are observed in most CRC patients. A decrease 
in the inhibitory proteins of the Wnt pathway can promote the 
proliferation and metastasis of CRC, and may be a determinant 
of a patient’s prognosis. DKK 1-3, WNT5A, and AXIN2 are neg-
ative regulators of the Wnt pathway, and they are frequently re-
pressed by promotor methylation in CRC.9,10 AXIN2, one of the 
genes that predicts high recurrence of surgically resected CRC, 
is derived from cancer stem cells and has been incorporated 
into methylation signatures.11 A German group reported that 
hypermethylation of TFAP2E results in downregulation of 
DKK4 and is a predictor of chemotherapy resistance in CRC.12 
CRC with loss of WNT5A expression and hypermethylation of 
WNT5A was reported to be associated with a poor prognosis 
in a previous study.13 
The aim of this study was to evaluate the prognostic value of 
the methylation status of four Wnt pathway genes (DKK3, WN-
T5A, AXIN2, and TFAP2E) in metastatic or recurrent CRC pa-
tients. In addition, we explored the prognostic impact of the 
methylation status of an additional six genes from the classic 
CIMP panel. 
MATERIALS AND METHODS
Study population
We included 236 patients with metastatic or recurrent CRC 
whose primary or metastatic tumor specimens were sufficient 
for evaluating methylation status by pyrosequencing. All pa-
tients were treated with first-line chemotherapeutics at Sever-
ance Hospital, Yonsei University from June 1999 to June 2010. 
Demographic and clinical information was obtained from the 
electronic medical records of Severance Hospital, and survival 
data were retrieved from the tumor registry at the Yonsei Cancer 
Center. Exclusion criteria comprised co-existing malignancies 
(except for non-melanoma skin cancer or in situ cervical can-
cer), cancer other than adenocarcinoma, and insufficient 
amount of formalin-fixed paraffin-embedded (FFPE) tumor 
tissue for DNA extraction. This study was approved by the In-
stitutional Review Board (IRB) at Yonsei University Severance 
Hospital, Seoul, Korea (IRB Number 4-2013-0134).
Tumor mutation and methylation analysis 
Genomic DNA from FFPE tissues was extracted using the 
QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA, USA). Ex-
tracted tumor DNA was used to evaluate the mutation status 
of KRAS at codons 12 and 13 and BRAF at codon 600 and the 
methylation status of six CpG islands from a classic CIMP panel 
(MINT1, MINT2, MINT31, hMLH1, p16, and p14) and four Wnt 
pathway-related genes (DKK3, WNT5A, AXIN2, and TFAP2E). 
The DNA was first treated with bisulfite, using an EZ Methyla-
tion kit (Zymo Research, Orange, CA, USA), and then pyrose-
quencing was performed using the PyroMark Q24 instrument 
(Qiagen). The detailed protocol for DNA mutation and meth-
ylation status evaluation using a pyrosequencer has been de-
scribed in previous reports.8,14 The methylation status of CpG 
island markers was based on a threshold value of 15% (nega-
tive, methylation level <15%; positive, methylation level ≥15%). 
The numbers of CpGs analyzed in the pyrosequencing assay 
were 2 for AXIN2, DKK3, and TFAP2E and 3 for WNT5A. Given 
that the concordance in methylation between the adjacent 
CpGs was very high for all four genes, we used average meth-
ylation for our analysis. A CIMP-positive tumor was defined as 
one in which two or more CIMP markers were methylation 
positive. Patients were divided into three groups based on the 
methylation status of the 10 evaluated genes (group 1, 0 meth-
ylation; group 2, 1−2 methylations; group 3, 3 or more methyl-
ations).
Treatment and efficacy assessment
All patients were treated with 5-fluorouracil, leucovorin, oxali-
platin, and irinotecan as single agents or in combination. The 
dose and schedule of the FOLFOX and FOLFIRI regimens were 
the same as those described in other studies or guidelines. As 
a routine clinical protocol, tumor assessment for response to 
chemotherapy was evaluated every 8 to 12 weeks, using CT 
scanning or magnetic resonance imaging in accordance with 
the Response Evaluation Criteria in Solid Tumors (RECIST) 
ver. 1.1. Overall survival (OS) was calculated from the first day 
of diagnosis to the day of death or the last follow-up visit. Pro-
gression-free survival (PFS) was calculated from the first day 
of chemotherapy to the time of the first documentation of pro-
gression, death from any cause, or the date of last follow-up 
visit if no events had occurred. Objective response rate (ORR) 
was calculated as the proportion of complete response (CR) 
and partial response (PR) by RECIST criteria. 
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Statistical analysis
Clinicopathologic variables were used as categorical vari-
ables. The difference in categorical variables and ORR was as-
sessed by the chi-square or Fisher’s exact test. Survival curves 
were estimated by the Kaplan-Meier method for OS and PFS, 
with 95% confidence interval (CI) for the median time to event. 
The log-rank test was used to compare the distribution of sur-
vival between groups in a univariate analysis. Multivariate 
analyses were carried out using the Cox proportional hazard 
regression model, including variables with p<0.10 in the uni-
variate analysis. Two-sided p-values of <0.05 were considered 
to indicate statistical significance. All analyses were performed 
using SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL, 
USA).
RESULTS
Baseline characteristics and genomic test 
A total of 194 patients had sufficient amounts of tumor DNA 
extract for methylation analysis (Table 1, Supplementary Tables 
1 and 2, only online). Approximately two-thirds (n=127) of the 
patients were male, and half (n=107) had metastatic CRC at 
the time of initial diagnosis. The primary tumor was located in 
the right and left side of the colon in 22.2% (n=43) and 77.9% 
(n=151) of patients, respectively. Microsatellite instability (MSI) 
status was known in 140 patients, of which five were MSI-high. 
Based on the classic definition of CIMP, 59 (30.4%) patients 
were classified as CIMP positive. Genomic tests of KRAS and 
BRAF and the methylation status of Wnt genes are summa-
rized in Table 2. Mutations in KRAS and BRAF were detected 
in 64 (33.0%) and 8 (4.1%) patients, respectively. CIMP-posi-
tive tumors harbored a significantly higher frequency of KRAS 
mutation than CIMP-negative tumors did (44.1% in CIMP+ vs. 
28.1% in CIMP-; chi-square, p=0.03) (Fig. 1). The frequency of 
BRAF mutation was also significantly higher in CIMP+ tumors 
(11.9% in CIMP+ vs. 0.7% in CIMP-; Fisher’s exact test, p=0.01) 
(Fig. 1). Based on methylation status, 38 (19.6%), 92 (47.4%), 
and 64 (33.0%) patients were divided into groups 1, 2, and 3, 
respectively. The mean number of methylations was higher in 
proximal-located CRC tumors (2.63, standard deviation 2.11) 
than in distal-located CRC tumors (1.91, standard deviation 
1.72). The most frequently methylated marker in group 3 was 
p16 (85.9%; 55 of 64 patients).
Methylation status and response to chemotherapy
Among the 194 patients included, 167 received palliative first-
line chemotherapy after diagnosis of metastatic or recurrent 
Table 1. Patient Characteristics 
Components Patients (n=194)
Sex, n (%)
Male 127 (65.5)
Female 67 (34.5)
Age (median, range) 62 (22−94)
ECOG PS, n (%)
0 118 (60.8)
1 76 (39.2)
Histology, n (%)
WD 9 (4.6)
MD 151 (77.8)
PD 12 (6.2)
Mucinous or Signet ring cell 22 (11.3)
Stage at the time of diagnosis, n (%)
Stage 2 24 (12.4)
Stage 3 63 (32.5)
Stage 4 107 (55.2)
Status at the study entry, n (%) 
Metastatic 106 (54.6)
Recurrent 78 (40.2)
No recurrence 10 (5.2)
Primary tumor location, n (%)
Ascending 38 (19.6)
Transverse 5 (2.6)
Descending 10 (5.2)
Sigmoid 50 (25.8)
Rectum 91 (46.9)
ECOG PS, Eastern Cooperative Oncology Group performance status; WD, 
well differentiated; MD, moderately differentiated; PD, poorly differentiated.
Table 2. Molecular Profile of Tumors 
Components Patients (n=194)
Microsatellite instability, n (%)
MSI-high 5 (2.6)
MSI-low 10 (5.2)
MSS 125 (64.4)
UA 54 (27.8)
CpG island methylator phenotype, n (%)
CIMP+ 59 (30.4)
CIMP- 135 (69.6)
Mutation status, n (%) 
KRAS 64 (33)
BRAF 8 (4.1)
Methylation, n (%)
p16 93 (47.9)
p14 21 (10.8)
MINT1 41 (21.1)
MINT2 31 (16)
MINT31 40 (20.6)
MLH1 1 (0.5)
DKK3 103 (53.1)
WNT5A 62 (32)
AXIN2 5 (2.6)
TFAP2E 4 (2.1)
UA, unavailable; MSI, microsatellite instability; MSS, microsatellite stable; 
CIMP, CpG island methylator phenotype.
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CRC. Surgical removal of metastatic lesions was amenable in 
39 (23.4%) patients, and they were excluded from the ORR 
analysis. The 27 patients who did not receive palliative chemo-
therapy were excluded from both the ORR and survival analy-
ses. More than two-thirds of the patients who received pallia-
tive first-line treatment were treated with either FOLFOX or 
FOLFIRI (n=114, 68.3%). The remaining patients were treated 
with either molecular targeted agents, such as bevacizumab or 
cetuximab (n=35, 20.9%), or single agents, such as 5-FU or 
Capecitabine (n=18, 10.8%). In 128 patients who did not under-
go metastasectomy, ORR (CR+PR) was observed in 63 (49.2%), 
and 10 (7.8%) had only non-measurable lesions according to 
the RECIST criteria. The number of methylations in a CRC tu-
mor sample was significantly associated with the ORR of first-
line chemotherapy (Fig. 2). The ORR was 66.7%, 46.3%, and 
43.2% in group 1, 2, and 3, respectively. Only one (4.2%) patient 
experienced progressive disease (PD) in group 1, whereas 
nine (13.4%) had PD in groups 2 and 3.
Methylation status and survival
With a median follow-up time of 38 months, 131 (67.5%) of the 
194 patients died. However, we only selected the 167 patients 
who received first-line chemotherapy for our survival analy-
sis. None of the 10 methylation sites was associated with OS in 
a univariate analysis. CIMP-positive patients exhibited a trend 
toward shortened survival, when compared with CIMP-nega-
tive patients (log-rank, p=0.16) (Fig. 3A). Nevertheless, we 
found that a higher number of methylations was associated with 
shorter OS. The median OS was 39.1, 39.7, and 29.1 months in 
groups 1, 2, and 3, respectively (log-rank, p=0.013) (Fig. 3B). In 
distal-located primary tumors, there was a statistically signifi-
cant association between the number of methylations and the 
OS (n=132, median OS 39.1 months in group 1 vs. 43.0 months 
in group 2 vs. 31.2 months in group 3; p=0.011); however, this 
was not observed in proximal-located tumors (n=35, median 
OS 34.7 months in group 1 vs. 25.5 months in group 2 vs. 29.1 
months in group 3; p=0.688). 
Group 1 had statistically non-significant longer PFS of first-
line chemotherapy than group 2 or 3 did. The median PFS was 
9.2, 7.6, and 7.0 months in groups 1, 2, and 3, respectively (log-
rank, p=0.198). In the 128 patients who did not undergo metas-
tasectomy, the median PFS was 9.1, 6.4, and 6.7 months, respec-
tively (log-rank, p=0.075). This trend toward improved survival 
in group 1 was also observed in the 39 patients who underwent 
metastasectomy: not reached, 49.6 months and 44.4 months in 
groups 1, 2, and 3, respectively (p=0.429).
Among the variables that were significantly associated with 
OS in the univariate analyses [age, Eastern Cooperative On-
cology Group performance status (ECOG PS), histologic grade, 
American Joint Committee on Cancer (AJCC) stage at diagno-
sis, BRAF mutation, resectability at the time of metastasis, objec-
tive response of chemotherapy], the number of methylations 
was independently associated with decreased survival in all 
patients (OS for 0–2 methylations vs. ≥3 methylations; hazard 
ratio, 1.72, 95% CI, 1.16–2.56; p=0.007) (Table 3).
DISCUSSION
In this study, we evaluated the methylation status of DKK3, 
WNT5A, AXIN2, and TFAP2E in patients with metastatic or 
recurrent CRC. Although a single methylation of one of the 
four genes was not associated with the prognosis of our sub-
jects, higher numbers of methylations among the 10 evaluated 
genes was independently associated with poorer clinical out-
come. In chemotherapy-treated CRC patients, OS was signifi-
cantly longer in groups 1 and 2 than in group 3. In patients with 
measurable disease, the ORR was significantly higher in group 
1 than in group 2 or 3, and the median PFS was numerically 
higher in group 1 than in group 2 or 3. 
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We selected four Wnt pathway genes and six classic CIMP 
panel genes because aberrant genomic or epigenomic changes 
of the Wnt signaling pathway are crucial in CRC carcinogene-
sis and progression. Methylation of DKK3 was present in 53.1% 
of our patients, and was not associated with survival. Similar-
ly, in a previous study by Yu, et al.,15 DKK3 methylation was 
detected in 67 of 128 (52.3%) patients with CRC tumors, and 
was not predictive of patient survival. However, they reported 
that DKK3 methylation status may be of potential use as a prog-
nostic marker in patients with gastric cancer who may benefit 
from aggressive treatment. Methylation of WNT5A has been 
detected in 18−54% of CRC tumors in previous studies.8,16,17 
WNT5A has been studied as an important functional and prog-
nostic marker in various cancers. In CRC, Rawson, et al.17 evalu-
ated the largest cohort of 1232 patients, and showed that WN-
T5A was strongly associated with sporadic MSI-high tumors 
without prognostic implication, in concordance with the pres-
ent study. These findings may indicate that the role of the Wnt 
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Fig. 3. Overall survival according to CpG island phenotype (A) and the number of methylations (B). CIMP, CpG island methylator phenotype.
Table 3. Univariate and Multivariate Analyses for Overall Survival 
Components Univariate HR (95% CI) p value Multivariate HR (95% CI) p value
Age ≥65 vs. <65 1.25 (0.88−1.78)   0.21 1.78 (1.07−2.98)   0.027
Male vs. Female 0.92 (0.64−1.32)   0.64 -
WD/MD vs. PD*/Mucin 0.52 (0.34−0.80)   0.003 0.37 (0.22−0.61) <0.001
ECOG PS 0 vs. 1 1.39 (0.98−1.97)   0.068 0.70 (0.42−1.15)   0.158
AJCC stage 2/3 vs. 4 2.02 (1.41−2.89) <0.0001 2.50 (1.70−3.79) <0.001
Proximal vs. Distal 1.00 (0.92−1.10)   0.96 1.11 (0.68−1.83)   0.679
BRAF mutation vs. wild type 2.38 (1.10−5.11)   0.027 1.36 (0.60−3.10   0.465
Metastasectomy Y vs. N 0.51 (0.31−0.83)   0.007 0.32 (0.13−0.80)   0.015
Objective response CR/PR vs. SD/PD† 1.97 (1.35−2.87) <0.0001 1.83 (1.21−2.77)   0.004
Bevacizumab/Cetuximab‡ used vs. not used 0.85 (0.61−1.17)   0.32 - -
CIMP positive vs. negative 1.30 (0.90−1.88)   0.16 -
DKK3 methyl vs. unmethyl 1.00 (0.71−1.41)   0.99 -
WNT5A methyl vs. unmethyl 1.25 (0.87−1.78)   0.23 -
AXIN2 methyl vs. unmethyl 1.60 (0.65−3.93)   0.3 -
TFAP2E methyl vs. unmethyl 1.89 (0.60−5.96)   0.28 -
Group 1/2 vs. 3 1.37 (0.96−1.96)   0.082 1.72 (1.16−2.56) 0.007
ECOG PS, Eastern Cooperative Oncology Group performance status; WD, well differentiated; MD, moderately differentiated; PD*, poorly differentiated; AJCC, 
American Joint Committee on Cancer; CR, complete response; PR, partial response; SD, stable disease; PD†, progressive disease; CIMP, CpG island methylator 
phenotype; group 1, no methylation; group 2, 1–2 methylation; group 3, 3 or more methylation; HR, hazard ratio; CI, confidence interval.
‡Bevacizumab was used in 22 patients and cetuximab was used in 16 patients.
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signaling pathway varies between CRC subtypes, depending 
on the epigenetic event of related genes. 
Methylation of AXIN2 and TFAP2E was detected only in 5 
(2.6%) and 4 (2.1%) patients, respectively, in the current study. 
Therefore, the number of patients was too small to analyze the 
prognostic impact of these genes. There are several possible 
reasons for why the frequency of methylation in both genes was 
lower than that reported in other western studies. First, the 
Asian ethnicity of our study population could have influenced 
the results. Yoon, et al.18 reported that CRC from Asians have a 
lower rate of BRAF and KRAS mutations than that from peo-
ple of African descent and Caucasians. Given that previous 
studies have reported that methylation of AXIN2 and TFAP2E 
is correlated with BRAF mutation, the tumors in our study 
population may have intrinsically lower rates of methylation. 
Second, the study method used to detect CpG island methyla-
tion was different from that used in previous studies. Pyrose-
quencing is not as sensitive, but is specific, for detecting meth-
ylation status, compared to methylation-specific PCR, which 
has been utilized in many previous studies. However, some 
proportions of AXIN2 and TFAP2E methylation could be false 
positives, given that miss-priming of methylation-specific 
PCR frequently occurs during experiments.19 In addition, low 
tumor purity or tumor heterogeneity of biopsy specimens from 
metastatic CRC patients may have contributed to the low fre-
quency of methylation: other studies examined the methyla-
tion status in operation specimens from early CRC patients. 
Wnt pathway methylation is easy to assess in routine clinical 
practice, when compared with whole-genome or transcrip-
tome analysis. In addition, the advantage of a DNA methyla-
tion marker is its stability and reproducibility, in contrast to 
RNA-based biomarkers, and actionability with demethylating 
agents, such as 5-Aza. Accordingly, recently, an international 
consortium attempted to share large-scale data and enable the 
classification of CRC into four consensus molecular subtypes 
(CMSs).20 CMS4 subtype CRC patients exhibit worse progno-
sis than patients with other subtypes, and show low Wnt activ-
ity, which might have resulted from repression of Wnt path-
way genes by CpG island methylation. Interestingly, De Sousa 
E Melo, et al.11 documented that a stem cell-derived gene sig-
nature (mesenchymal features with chemotherapeutic resis-
tance and high TGF-β signaling) was closely related to meth-
ylation-dependent tuning of the Wnt expression program. 
The main limitations of our study are its retrospective na-
ture and the heterogenous treatment protocols. Therefore, our 
results need to be validated in future prospective studies. An-
other study limitation is that we did not evaluate the extended 
RAS mutations (in exons 3 and 4 of KRAS and exons 2, 3, and 
4 of NRAS) or the MSI status of all patients. However, this should 
not have a significant impact on our results because most of 
our patients did not receive anti-EGFR monoclonal antibody. 
Lastly, the absence of a consensus panel defining CIMP sub-
groups is a hurdle to be overcome with comparison with other 
future studies. 
In conclusion, we found that a higher number of methyl-
ations among the 10 genes evaluated, comprising four Wnt 
pathway genes and six classic CIMP panel genes, was inde-
pendently associated with poorer clinical outcomes in CRC 
patients. Further validation of these markers in prospective 
settings and early stage patients will guide CRC patients to 
more personalized treatment planning and, hopefully, improve 
clinical outcomes in the future. 
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